NASDAQ · SERVICES-MEDICAL LABORATORIES · SMALL CAP
Exagen Inc. XGN
8 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$66.6M
▲ 19.7% vs FY2024
EPS · FY25
$-0.93
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-147.8%
Net margin · FY25
-30.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 66.6M
Revenue, FY2025 · full 8-year series below
Revenue
Net income
The company lost 30 cents on every revenue dollar this year.
Per share
USD -0.93
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-147.8%
Return on equity, FY2025
ROE
Operating margin-21.1%
Net margin-30.0%
Return on assets-38.8%
Each USD of equity lost 148 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+9.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+13.5%
+9.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2025
Change, 5 years+81.1%
Change, 10 years—
The share count grew 81% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 58.0M
total assets, end of FY2025
Total assetsUSD 58.0M
EquityUSD 17.4M
CashUSD 32.2M
Gross debtUSD 22.9M
Net debtUSD -9.3M
Current ratio3.45×
The company holds more cash than debt.
History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue $B
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
−0.0
0.0
−0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.93
−0.83
−1.34
−2.77
−1.68
−1.32
−8.46
−293.34
Dividend / sh $
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
ROE %
−147.8
−93.8
−72.7
−74.4
−42.4
−34.2
·
·
Shares out B
0.02
0.02
0.02
0.02
0.02
0.01
0.01
0.00
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
25 of 27
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 2 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed